High efficacy of 8 weeks paritaprevir/ritonavir/ombitasvir and dasabuvir among people with recent HCV genotype 1 infection

Martinello M [1], Cerrone M [2], Bhagani S [3], Orkin C [4], Cooke G [5], Gane E [6], Petoumenos K [1], Applegate TL [1], Tu E [1], Marks P [1], Pagani N [2], Grebely J [1], Dore GJ [1,7], Nelson M* [2], Matthews GV* [1,7]

*joint senior author

1. Kirby Institute, UNSW Sydney, Sydney, Australia; 2. Chelsea and Westminster Hospital, London, UK; 3. Royal Free Hospital, London, UK; 4. Royal London Hospital, London, UK; 5. Imperial College NHS Trust, St Mary's, London, UK; 6. Auckland City Hospital, Auckland, New Zealand; 7. St Vincent's Hospital, Sydney.

Disclosures

- Dr M Martinello has received speaker payments from Abbvie

Funding:

- The Kirby Institute is funded by the Australian Government Department of Health and Ageing.
- Research reported in this publication was supported by Abbvie as an investigator-initiated study.

TARGET3D, Cohort One: Background

With interferon-free DAA therapy established as the standard of care for chronic HCV, the optimal management of acute (<6 months) and recent (<12 months) HCV infection is yet to be defined.

Duration? Regimen?

Shortened duration DAA therapy may be appropriate for individuals with recent HCV infection.

Aim: To assess the efficacy and safety of paritaprevir-ritonavir-ombitasvir and dasabuvir with or without ribavirin for eight weeks in individuals with acute or recent HCV infection.

TARGET3D, Cohort One: Methods



Recent primary HCV infection was defined as 1st positive anti-HCV Ab and/or HCV RNA within 6 months of enrolment and one of the following:

1. HCV seroconversion within 18 months
2. Acute clinical hepatitis within 12 months (jaundice or ALT >10x ULN)
3. Acute asymptomatic hepatitis within 12 months (ALT >5x ULN)

Recent HCV reinfection was defined as new positive HCV RNA within 6 months of enrolment, following previous clearance (positive HCV Ab and undetectable HCV RNA on ≥2 occasions 6 months apart).

TARGET3D, Cohort One: Results

Baseline characteristics	ITT (n=30)
Primary HCV infection, n (%) Reinfection, n (%)	26 (87) 4 (13)
Injecting drug use (ever), n (%)	16 (53)
HIV infection, n (%)	23 (77)
Mode of HCV acquisition, n (%) Injecting drug use Sexual exposure – GBM Occupational	 8 (27) 21 (70) 1 (3)
Duration of infection (weeks), median (range)	30 (11, 51)
Baseline HCV RNA Log_{10} IU/mL, median (range) >1,000,000 IU/mL (>6log_{10}), n (%)	 5.7 (2.7, 7.3) 13 (43)



Treatment outcome	All (n=29)	HCV (n=6)	HIV/HCV (n=23)
SVR12 ITT	**29 (97)**	**6 (86)**	**23 (100)**
Virologic failure	0	0	0
Discontinuation	1 (3)	1	0

TARGET3D, Cohort One: Results



No impact of baseline HCV RNA on efficacy

Baseline HCV RNA >6 log_{10}: SVR12 100% (13/13)

Acknowledgements

Principal Investigators
A/Prof. Gail Matthews
Prof. Mark Nelson

UNSW Sydney
Prof. Greg Dore
A/Prof. Jason Grebely
Ms. Pip Marks
Dr Elise Tu
Dr. Tanya Applegate
Ms. Ecaterina Filep
Dr. Kathy Petoumenos

Collaborators
Dr. Sanjay Bhagani (UK)
Dr. Graham Cooke (UK)
Prof. Edward Gane (NZ)
Prof. Margaret Hellard (Aus)
Dr. Ranjababu Kulasegaram (UK)
Dr. Chloe Orkin (UK)
A/Prof. David Shaw (Aus)

Site coordinators and study staff
Patients and their families

Cohort Two
HCV genotype 1-6
Glecaprevir/pibrentasvir for 6 weeks
Closed to recruitment (n=30)